Applaud Trade, Avoid Price Controls

REALCLEAR HEALTH

In an era where American leadership on the global stage has been redefined by bold, unapologetic negotiation, President Trump has proven himself a master of the art of the deal and using existing and creating new leverage. From renegotiating NAFTA into the USMCA in the first term, extracting concessions from China through targeted tariffs, to pressuring European allies on defense spending and trade imbalances, his administration has wielded trade policy like a precision tool.  These efforts have not only protected American workers and industries but have also forced trading partners to reckon with decades of unfair practices.

Yet, one area gives pause: the push for a Most Favored Nation (MFN) clause in drug pricing.

Applying a form of price controls to pharmaceuticals risks undermining innovation, patient access, and the very economic strength he's fought to bolster.

Let's first celebrate what the president has gotten right in his two terms as President. His approach to trade has been a breath of fresh air in Washington long dominated by multilateral complacency.

Read more here.